Filtered By:
Condition: Hughes Syndrome

This page shows you your search results in order of relevance. This is page number 18.

Order by Relevance | Date

Total 523 results found since Jan 2013.

Neurovascular Manifestations of Iron-Deficient Anemia: Narrative Review and Practical Reflections through a Teaching Case
Conclusions: IDA is a common but treatable condition that, independently or synergically, may increase the risk of thrombotic events. The diagnostic and therapeutic approach has not yet been defined, and each case should be individually addressed in a pragmatic clinical road map.PMID:36294407 | DOI:10.3390/jcm11206088
Source: Clinical Lung Cancer - October 27, 2022 Category: Cancer & Oncology Authors: Marialuisa Zedde Giacomo Portaro Laura Ferri Francesco Cavallieri Manuela Napoli Claudio Moratti Fabrizio Piazza Franco Valzania Rosario Pascarella Source Type: research

Recurrent embolic strokes due to antiphospholipid syndrome and non-bacterial thrombotic endocarditis in a patient with basal cell carcinoma
CONCLUSION: Outside of SLE and antiphospholipid syndrome, NBTE is a rare and underdiagnosed disease associated with thromboembolic events. Adequate anticoagulation is a cornerstone of its treatment. Anticoagulation management during perioperative care and valve surgery deserves specific attention and helps to protect the patient from embolic complications. In the case of stroke and thromboembolic events of unclear cause or suspected NBTE, echocardiography and thrombophilia assessments including an immunological workup are recommended.PMID:37170311 | DOI:10.1186/s13019-023-02266-6
Source: Hand Surgery - May 11, 2023 Category: Surgery Authors: Julianna Svantner Luc Lavanchy Ania Labouch ère Source Type: research

Therapeutic challenges after successful thrombectomy in a patient with an antiphospholipid syndrome associated M1-occlusion: A case report.
CONCLUSION: This case report showed the feasibility of mechanical clot retrieval and stent implantation in patients with APS. Due to the elevated risk of in-stent thrombosis a prolonged therapy with glycoprotein (GP)IIb/IIIa receptor antagonists in the initial postoperative period and further anticoagulation with coumarin derivate might be needed. PMID: 26135672 [PubMed - as supplied by publisher]
Source: Interventional Neuroradiology - July 4, 2015 Category: Radiology Tags: Interv Neuroradiol Source Type: research

Antiphospholipid Antibodies and Recurrent Thrombotic Events: Persistence and Portfolio
Conclusions: Rates of TOE/death were not influenced by aPL results at baseline or follow-up. Persistent anti-β2GPI alone, and with persistent second aPL, was independently associated with decreased time to TOE/death. Persistent aPL, an aPL portfolio and newer aPL in ischemic stroke patients are not helpful in predicting an increased rate of recurrent TOEs.Cerebrovasc Dis 2015;40:293-300
Source: Cerebrovascular Diseases - October 30, 2015 Category: Neurology Source Type: research

Fatal antiphospholipid syndrome following endoscopic transnasal-transsphenoidal surgery for a pituitary tumor: A case report
Conclusion: If patients have a history of cerebral stroke in their early life, such as a young stroke, the APS and higher risk of developing fatal APS after major surgery should be considered. The optimal management of APS remains controversial. The best treatment strategies are only early diagnosis and aggressive therapies combing of anticoagulant, corticosteroid, and plasma exchange. The intravenous immunoglobulin is prescribed for patients with refractory APS.
Source: Medicine - January 1, 2017 Category: Internal Medicine Tags: Research Article: Clinical Case Report Source Type: research

Transcranial Doppler findings in antiphospholipid syndrome.
CONCLUSIONS: Patients with APS had a higher frequency of RLS than healthy controls. This finding alerts to the importance of cardiac investigation in patients with stroke and APS, because further therapies such as RLS occlusion might eventually add protection. The higher frequency of MES in patients with SLE could suggest an effect of anticoagulant therapy on MES prevention, more frequently used in patients with APS. PMID: 30755144 [PubMed - as supplied by publisher]
Source: Lupus - February 12, 2019 Category: Rheumatology Authors: Ricarte IF, Dutra LA, Barsottini OGP, Souza AWS, Andrade DCO, Mangueira C, Silva GS Tags: Lupus Source Type: research

New versus Old Oral Anticoagulants: How Can We Set the Scale Needle? Considerations on a Case Report.
We report the case of a 41-year-old woman with antiphospholipid syndrome who was unsuccessfully treated with Dabigatran, a new oral anticoagulant, as she developed a major stroke involving the right carotid artery, due to deep venous thrombosis with pulmonary embolism. We therefore suggest a closer monitoring of the safety and efficacy of dabigatran. Moreover, in the presence of multifactorial causes of pro-coagulation, we believe that warfarin should remain the mainstay of oral anticoagulation. PMID: 30884868 [PubMed - in process]
Source: Medicina (Kaunas) - March 16, 2019 Category: Universities & Medical Training Authors: Arcadi FA, Portaro S, Giorgianni R, Naro A, Casella C, Genovese C, Marino S, Calabrò RS Tags: Medicina (Kaunas) Source Type: research

Blood Cell-Bound C4d as a Marker of Complement Activation in Patients With the Antiphospholipid Syndrome
In conclusion the detection of complement activation products on circulating erythrocytes and platelets using a highly sensitive and specific assay further supports the view that APS is a complement-mediated disorder. Increased EC4d and PC4d percentages are associated with the active inflammatory disease in SLE. It is difficult to translate this finding to APS which is a non-acute inflammatory disorder. We failed to find an association with both the classification and non-classification criteria, including thrombocytopenia. However, we believe that this sensitive tool to evaluate complement activation may offer more inform...
Source: Frontiers in Immunology - April 11, 2019 Category: Allergy & Immunology Source Type: research

Sneddon syndrome: a comprehensive clinical review of 53 patients
ConclusionsSS predominantly affects young women with a relatively large number of cardiovascular risk factors. Clinical features of SS are comparable across different studies. We found no differences in the main clinical features between APL-positive and APL-negative patients.
Source: Journal of Neurology - January 29, 2021 Category: Neurology Source Type: research

Anticoagulant choice in antiphospholipid syndrome – associated thrombosis
Background: DOACs have largely replaced VKAs as first-line therapy for venous thromboembolism in patients with adequate renal function. However, there is concern in APS that DOACs may have higher rates of recurrent thrombosis than VKAs when treating thromboembolism. Dr. David Portnoy Study design: Randomized noninferiority trial. Setting: Six teaching hospitals in Spain. Synopsis: Of adults with thrombotic APS, 190 were randomized to receive rivaroxaban or warfarin. Primary outcomes were thrombotic events and major bleeding. Follow-up after 3 years demonstrated new thromboses in 11 patients (11.6%) in the DOAC...
Source: The Hospitalist - December 10, 2021 Category: Hospital Management Authors: Daniel Hickman Tags: Hematology Thrombosis Source Type: research

Case report: MELAS and concomitant presumed antiphospholipid antibody syndrome in an adult woman
Mitochondrial encephalomyopathy, lactic acidosis, stroke-like episodes, and other features (short stature, headaches, seizures, and sensorineural hearing loss) constitute characteristics of MELAS syndrome. MELAS is a rare condition due to mutations in maternally inherited mitochondrial DNA with levels of heteroplasmy possibly related to late adulthood presentation. A previously reported MELAS case coexisted with presumed Antiphospholipid Antibody Syndrome (APLAS), but the connection between MELAS and a potential APLAS is unclear. A 29-year-old woman presented with mild right-sided sensorimotor symptoms and mixed aphasia in...
Source: Frontiers in Neurology - December 14, 2022 Category: Neurology Source Type: research

Cerebral small-vessel disease associated with COL4A1 and COL4A2 gene duplications
A nonsmoking woman, aged 44 years, presented with transient right-sided hemiparesis. CT showed leukoencephalopathy without infarction (figure). Blood pressure was normal. Blood count, plasma glucose levels, C-reactive protein, renal/liver function tests, cardiac enzymes, atrial natriuretic factor, HIV/syphilis/hepatitis B and C serology, and lactic acid levels were normal. Low-density lipoprotein (LDL) cholesterol levels were slightly elevated (1.25 g/L). Screening tests for prothrombotic disorders (serum fibrinogen, D-dimer, fibrin degradation products, antithrombin III level, protein C and S level, factor V Leiden, proth...
Source: Neurology - September 8, 2014 Category: Neurology Authors: Renard, D., Mine, M., Pipiras, E., Labauge, P., Delahaye, A., Benzacken, B., Tournier-Lasserve, E. Tags: Stroke in young adults, MRI, All Cerebrovascular disease/Stroke, Infarction, All Genetics CLINICAL/SCIENTIFIC NOTES Source Type: research

Anticoagulation for Noncardiac Indications in Neurologic Patients: Comparative Use of Non-Vitamin K Oral Anticoagulants, Low-Molecular-Weight Heparins, and Warfarin
Opinion statement Patients with neurologic disorders may develop a wide variety of thromboembolic events, both as a primary manifestation and as a consequence of their underlying neurologic condition. There are many available options for anticoagulation, ranging from warfarin to the parenteral subcutaneously administered anticoagulants to the non-vitamin K oral anticoagulants (NOACs). Warfarin is orally available, well-studied, and easily reversible in the setting of bleeding, but has a prolonged onset of action, measured in days, and equally slow offset; requires frequent monitoring for dose titration; and has m...
Source: Current Treatment Options in Neurology - July 19, 2014 Category: Neurology Source Type: research

Clinical, laboratory, and therapeutic analyses of 21 patients with neonatal thrombosis and antiphospholipid antibodies: a literature review.
CONCLUSION: Neonatal thrombosis and antiphospholipid antibodies are rare. The development of thrombotic manifestations in neonates seems not to be associated exclusively with the aPL, but their etiology may be linked to pre- and perinatal events. We noted good therapeutic responses, especially in stroke patients, who presented with favorable outcomes in 82% of the cases. PMID: 25133197 [PubMed - in process]
Source: Journal of Immunology Research - November 19, 2014 Category: Allergy & Immunology Tags: J Immunol Res Source Type: research